Latest News

  • Kalbe Collaborates with Genexine of South Korea to Develop COVID-19 Vaccines

    Wednesday, May 27, 2020
    Kalbe Collaborates with Genexine of South Korea to Develop COVID-19 Vaccines

    Jakarta, May 27, 2020, PT Kalbe Farma Tbk (Kalbe) signed a memorandum of understanding with Genexine, Inc., a biological drug company from South Korea to develop a vaccine for the new corona virus or Covid-19 . Kalbe and Genexine has agreed to conduct GX-19 clinical trials in Indonesia, that is the development of DNA vaccines against new corona virus, to be carried out by the consortium of Genexine, Binex, the International Vaccine Institute (IVI), GenNBio, the Korea Advanced Institute of Science & Technology (KAIST), and Pohang University of Science & Technology (POSTECH). Covid-19 vaccine clinical trial is planned to be conducted in June 2020. 

  • Kalbe Donated Hand Sanitizers to COVID-19 Referral Hospitals in Jabodetabek

    Friday, May 22, 2020
    Kalbe Donated Hand Sanitizers to COVID-19 Referral Hospitals in Jabodetabek

    Jakarta, 22 May 2020, PT Kalbe Farma Tbk (Kalbe) through the Kalbe Consumer Health Division donated hand sanitizers to several COVID-19 Referral Hospitals in Jabodetabek via the National Disaster Management Agency (BNPB). The presentation of the 5,000 bottles of hand sanitizer was symbolically carried out by Feni Herawati, Director of Consumer Health Division of PT Kalbe Farma Tbk to Colonel Cba Agung Maryono, Sub Commander of the Supplies and Donations Task Force of the Emergency COVID-19 Hospital of Wisma Atlet, Jakarta. 

  • Kalbe to Distribute Dividend of Rp 937.5 Billion

    Monday, May 18, 2020
    Kalbe to Distribute Dividend of Rp 937.5 Billion

    Jakarta, May 18, 2020 – PT Kalbe Farma Tbk (“Kalbe” or “the Company”) will distribute cash dividend of Rp 937.5 Billion. The dividend distribution of Rp 20 per share or equivalent to a dividend payout ratio of around 37% of fiscal year 2019 net income, has been approved by the shareholders of the Company in the Annual General Meeting of Shareholders (“AGMS”) held on May 18, 2020 in Gedung Bintang Toedjoe, Pulomas, Jakarta. In compliance with the prevailing regulations, dividend payment will be made at the latest within 30 days after the announcement of AGMS where the Company will shortly announce the schedule and procedures.

  • Kalbe Develops Natural Cordyceps Mushrooms as Early Protection Against COVID-19 by Strengthening Body Immunity

    Wednesday, May 13, 2020

    Jakarta, May 13, 2020, PT Kalbe Farma Tbk (Kalbe) through the Kalbe Consumer Health division with the Health & Happiness (H2) product Cordyceps militaris held health education event of maintaining body immunity through natural ingredients during the COVID-19 pandemic. H2 Cordyceps militaris, derived from the mushroom Cordyceps militaris that is naturally processed, contains cordycepin and adenosine, which can help to strengthen the body's immunity.

RSS
12345Last